Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers

  • Cancer Res. 1999 Nov 15;59(22):5683-6.
S H Lee  1 ,  M S Shin ,  H S Kim ,  H K Lee ,  W S Park ,  S Y Kim ,  J H Lee ,  S Y Han ,  J Y Park ,  R R Oh ,  J J Jang ,  J Y Han ,  J Y Lee ,  N J Yoo
Affiliations
  • 1. Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul.
PMID: 10582684
Abstract

Chromosome 8p21-22 is a frequent site of allelic deletions in many types of human Tumors, including Non-Small Cell Lung Cancer (NSCLC). Tumor necrosis factor-related apoptosis-inducing ligand-receptor 2 (TRAIL-R2) is a cell-surface receptor involved in cell death signaling. The TRAIL-R2 gene recently has been mapped to chromosome 8p21-22. To explore the possibility that the TRAIL-R2 gene might be the relevant gene to the frequent deletion of 8p21-22 in NSCLC, we have analyzed the entire coding region and all splice sites of TRAIL-R2 for the detection of the somatic mutations in a series of 104 NSCLCs. Overall, 11 Tumors (10.6%) were found to have TRAIL-R2 gene mutations in the death domain known to be involved in the transduction of an apoptotic signal. Our data indicate that somatic mutation of TRAIL-R2 may play a role in the pathogenesis of some NSCLCs and that the TRAIL-R2 gene is one of the genes relevant to the frequent loss of chromosome 8p21-22 in NSCLC.